樂觀
$100.54
情境價格
$85.710
-0.266 (-0.31%)收盤時
U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 795 outpatient physical therapy clinics in 45 states. Its reportable segments include the Physical Therapy Operations segment and the Industrial Injury Prevention Services (IIP) segment. The Physical Therapy Operations segment consists of physical therapy, speech therapy and occupational therapy clinics and home-care physical and speech therapy practices that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders, sports-related injuries, and rehabilitation of injured workers. The IIP segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers.
US Physical Therapy Inc is a good buy right now due to its current price of $85.71, which is below the analyst price target range of $90 to $98, indicating potential upside. Additionally, the company has shown a revenue growth of 8.5% year-over-year in Q2 2026, reaching $214.06 million, despite a recent earnings miss. The RSI is at 61.36, suggesting that the stock is in a healthy momentum range, and the forward P/E ratio of 27.25 indicates reasonable valuation compared to growth prospects. However, a key risk is the recent earnings miss, with EPS reported at $0.25, missing expectations by $0.53, which could impact investor sentiment.
JPMorgan
$95
2026-09-11
JPMorgan
2026-09-11
目標價
$95
Barrington
$98
2026-08-10
Barrington
2026-08-10
目標價
$98
Barrington
$90
2026-05-13
Barrington
2026-05-13
目標價
$90
Citizens
$98
2026-05-08
Citizens
2026-05-08
目標價
$98
Jefferies
$102
2026-03-09
Jefferies
2026-03-09
目標價
$102
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

U.S. Physical Therapy Appoints New Board Member

U.S. Physical Therapy CEO Presents at Midwest Ideas Conference

U.S. Physical Therapy Appoints New CFO

USPH (USPH) Q2 2026 Earnings Call Transcript

U.S. Physical Therapy Reports Q2 Earnings Miss with Revenue Beat
U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 795 outpatient physical therapy clinics in 45 states. Its reportable segments include the Physical Therapy Operations segment and the Industrial Injury Prevention Services (IIP) segment. The Physical Therapy Operations segment consists of physical therapy, speech therapy and occupational therapy clinics and home-care physical and speech therapy practices that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders, sports-related injuries, and rehabilitation of injured workers. The IIP segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).
US Physical Therapy Inc is a good buy right now due to its current price of $85.71, which is below the analyst price target range of $90 to $98, indicating potential upside. Additionally, the company has shown a revenue growth of 8.5% year-over-year in Q2 2026, reaching $214.06 million, despite a recent earnings miss. The RSI is at 61.36, suggesting that the stock is in a healthy momentum range, and the forward P/E ratio of 27.25 indicates reasonable valuation compared to growth prospects. However, a key risk is the recent earnings miss, with EPS reported at $0.25, missing expectations by $0.53, which could impact investor sentiment.
7 analysts cover USPH: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 101.50.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。